Professor Graham Boulnois, PhD - Partner

Focus: Biotechnology

Summary:
Professor Graham Boulnois joined SVLS as a Venture Partner in 2001 and became a Partner in 2004. Graham is a Director of ESBATech, Oxagen, Affinium and Vantia. He has responsibility for overseeing the investment in Cellzome and the SVLS loan to X2 Pharma. He was a Director at Lorantis and also Alantos prior to its sale to Amgen.

Prior Experience:
Before joining SVLS, Graham was Senior Vice President in the R&D function at Aventis Pharma where he had global responsibility for Lead Generation. Prior to joining Aventis, Graham spent a number of years at Zeneca Pharmaceuticals as Senior Vice President, Discovery Research and then with AstraZeneca Pharmaceuticals as Global Vice President, Enabling Science and Technology. Before joining the pharmaceutical industry, he was Professor of Microbiology, Chairman of Biological Sciences and Pro-Dean of the Science Faculty at Leicester University.

Qualifications:
Graham has a BSc in Biological Science and a PhD in Molecular Biology from the University of Leicester.